American Century Companies Inc. Increases Stake in Emergent BioSolutions Inc. (NYSE:EBS)

American Century Companies Inc. grew its position in Emergent BioSolutions Inc. (NYSE:EBS) by 23.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,137,712 shares of the biopharmaceutical company’s stock after buying an additional 404,667 shares during the period. American Century Companies Inc. owned approximately 3.95% of Emergent BioSolutions worth $20,437,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Emergent BioSolutions by 8.3% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 902,332 shares of the biopharmaceutical company’s stock worth $8,626,000 after acquiring an additional 69,157 shares during the last quarter. Prescott Group Capital Management L.L.C. raised its stake in shares of Emergent BioSolutions by 250.0% in the fourth quarter. Prescott Group Capital Management L.L.C. now owns 210,000 shares of the biopharmaceutical company’s stock worth $2,008,000 after purchasing an additional 150,000 shares during the last quarter. E Fund Management Co. Ltd. bought a new position in shares of Emergent BioSolutions during the fourth quarter valued at $98,000. SBI Securities Co. Ltd. purchased a new stake in shares of Emergent BioSolutions during the fourth quarter valued at $63,000. Finally, Wolverine Asset Management LLC bought a new stake in Emergent BioSolutions in the 4th quarter worth about $1,303,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Stock Performance

NYSE:EBS opened at $4.68 on Monday. The stock has a 50-day simple moving average of $8.04 and a two-hundred day simple moving average of $8.65. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions Inc. has a 52-week low of $1.82 and a 52-week high of $15.10. The firm has a market capitalization of $254.03 million, a PE ratio of -1.14 and a beta of 1.80.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.40. The firm had revenue of $194.70 million during the quarter, compared to analysts’ expectations of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same period in the prior year, the company posted ($0.77) earnings per share. Analysts forecast that Emergent BioSolutions Inc. will post -0.63 EPS for the current year.

Insider Activity

In other news, Director Neal Franklin Fowler sold 35,000 shares of Emergent BioSolutions stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the sale, the director now directly owns 101,100 shares of the company’s stock, valued at approximately $589,413. The trade was a 25.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Emergent BioSolutions in a research note on Friday, March 21st. StockNews.com downgraded shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.